Regor Therapeutics Reports Phase 2a Results for RGT-075
Regor Therapeutics Group recently shared its findings from a Phase 2a clinical trial for RGT-075, an oral GLP-1 receptor agonist designed to assist in weight management. This innovative drug was evaluated during a 12-week study where patients recorded a notable 5% placebo-adjusted weight loss with a remarkably low discontinuation rate of only 4%, similar to that of the placebo group.
Highlights of the Clinical Trial Findings
In the Phase 2a trial, which spanned ten clinical centers, participants using RGT-075 at a dosage of 125 mg once daily achieved statistically significant results compared to those on placebo. Throughout the trial, only 4% of the participants discontinued treatment due to adverse effects, illustrating the tolerability of the medication.
Tolerability and Safety Profile
No severe treatment-related adverse events were recorded, showcasing the safety of RGT-075. While some mild-to-moderate side effects such as nausea and vomiting were observed in 40% of participants, Regor's data highlights a promising safety profile reflective of established GLP-1 treatments.
Regor’s Next Steps with RGT-075
In light of the favorable Phase 2a results, Regor is set to launch a further Phase 2b study known as COMO-1. This clinical trial aims to explore various dosages of RGT-075 to ascertain its effectiveness in a broader patient population with obesity and related conditions. The COMO-1 study is set to involve around 240 adults over 36 weeks, with results expected by the end of 2025.
Study Design and Objectives
Participants in the COMO-1 trial will be randomized to receive either RGT-075 or a placebo, with the primary endpoint focused on the percentage change in body weight from baseline to week 36. Secondary endpoints will assess safety, tolerability, and pharmacokinetics, paving the way for insights that will inform future studies.
Regor’s Commitment to Innovative Solutions
Dr. Xiayang Qiu, CEO of Regor, emphasized the potential of RGT-075 as a groundbreaking oral solution for managing obesity and related comorbidities, fulfilling a vital demand in the healthcare market. The urgency for effective and accessible treatment options is more significant than ever, given the rising obesity rates globally.
About RGT-075 and Its Development
RGT-075 represents a promising advance in obesity treatment given its oral bioavailability and full agonist nature for GLP-1 receptors. Earlier studies have demonstrated its efficacy and safety profile, establishing it as a competitive alternative to peptide-based medications already present in the market.
About Regor Therapeutics Group
Regor Therapeutics is at the forefront of biotechnology innovation, addressing unmet health needs in oncology and metabolic diseases. Leveraging their unique rCARD™ drug discovery platform, Regor is proficient in rapidly developing small molecules that target critical health conditions.
Frequently Asked Questions
What is RGT-075?
RGT-075 is an oral GLP-1 receptor agonist designed to aid in weight management and address obesity-related health issues.
What were the key findings from the Phase 2a trial?
The trial showcased a 5% placebo-adjusted weight loss with a low discontinuation rate and no severe adverse events linked to the treatment.
What is the next step for Regor Therapeutics?
Regor will commence the COMO-1 Phase 2b study to evaluate different dosages of RGT-075 and further investigate its efficacy and safety.
What is the expected timeline for upcoming results?
Topline data from the Phase 2b trial are anticipated by the end of 2025.
Where can I learn more about Regor Therapeutics?
For more information, please visit Regor Therapeutics’s official website.
